Varian Oncology Systems Signs Joint Marketing Agreements With Medison America, Inc. For Prostate Brachytherapy, 3D Ultrasound.
Firms Will Also Collaborate On Developing Other Image-Guided Products
Varian Oncology Systems today announced the signing of agreements with Medison America, Inc., and its Cone/Medison joint venture, to jointly market certain of the firms' products for applications in radiation oncology, urology, and gynecology.
The primary aim of the agreements, according to the companies, is an enhanced cooperation in the field of prostate brachytherapy utilizing 3D ultrasound, where urologists and radiation oncologists collaborate to treat cancer with permanent or temporary radioactive seed implants.
The products covered under the agreements are Varian's VariSource high dose rate brachytherapy system, the Voluson 530D 3D ultrasound system from Medison America, and the Combison 301 ultrasound system from Cone/Medison.
"The unique three-dimensional capabilities of the Voluson 530D system, together with our treatment planning capabilities for prostate brachytherapy, offer an extraordinary opportunity to extend the quality assurance and efficiency of these procedures," said Varian's David Hall, Ph.D., VariSource product manager. "This combination of technologies is specifically designed to make brachytherapy easier and has the potential to be of considerable benefit to up to 200,000 American males per year."
"Medison's advanced 3D ultrasound technology has the capability of direct digital electronic input for real-time monitoring and optimization of treatment plans," said Peter Klein, president and chief executive officer of Medison America, Inc. "This partnership with Varian, the world leader in radiation therapy products, opens significant new markets for applications of 3D ultrasound in cancer therapy."
The firms said their research collaboration will be focused on developing new applications of the three-dimensional ultrasound technology for other image-guided therapies in the treatment of cancer and other disorders. Varian's efforts in this area will be carried out through a subsidiary, Varian Biosynergy Inc., according to its president, Robert Sutherland, Ph.D.
Varian Oncology Systems and Varian Biosynergy are units of the $500 million Health Care systems business of Varian Associates, Inc.
Varian Associates, Inc., is the world's leading manufacturer of medical linear accelerators and related radiotherapy products for the treatment of cancer. The more than 3,500 Varian systems in service around the world treat over one million patients annually. Varian is also the premier manufacturer of x-ray tubes used in CT scanners and mammography and other medical imaging systems. A diversified, high technology company with annual sales of $1.4 billion, Varian is based in Palo Alto, Calif.
Medison America, Inc. is a world-leading manufacturer of diagnostic ultrasound equipment. Medison's advanced 3D and multi-planar reconstruction ultrasound technology is redefining the use of ultrasound. Medison has operations and R&D facilities in the United States, Europe, and Asia, widespread medical product manufacturing and an installed base of over 45,000 systems. Medison is based in Pleasanton, Calif.
Cone/Medison is a joint venture between Medison America, Inc. and Cone Instruments concentrating on selling Medison's new C301 ultrasound product into the emerging urology market. Cone/Medison is based in Solon, Ohio.
CONTACT: Varian Gary Simpson, 650/424-5782 firstname.lastname@example.org
|Printer friendly Cite/link Email Feedback|
|Date:||May 28, 1998|
|Previous Article:||ABAG to Convene Regional Hearing on BofA Merger; Supervisors Mary King and Michael Yaki Make the Request.|
|Next Article:||Xenometrix Receives Extension on Bridge Notes.|